Although there is growing evidence that estrogens promote tumor progression in epithelial ovarian cancer, the molecular mechanisms accounting for this are still unclear. Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The molecular mechanisms of the effects of SERMs such as raloxifene on the tumor progression of epithelial ovarian cancer are also still unclear. Here, we show that various genomic actions of estrogen differ from those of raloxifene in human ovarian cancer cell lines expressing estrogen receptor a (ERa). 17b-Estradiol (E2) induced the gene expression of c-Myc and IGF-1 and increased the binding of ERa to the AP1 site of the promoters of c-Myc and IGF-1. ERa silencing abolished the E2-stimulated c-Myc expression. E2 induced the recruitment of co-activators such as SRC-1, SRC-3 and CBP to the promoters of c-Myc and IGF-1, and SRC-1 silencing abolished both the E2-stimulated c-Myc expression and cell-cycle progression. In contrast, although raloxifene increased the binding of ERa to the AP1 site of the promoters of c-Myc and IGF-1, raloxifene had no effect on the gene expression of c-Myc or IGF-1. Raloxifene induced the recruitment of co-repressors such as HDAC2, N-CoR and SMRT to the promoter of IGF-1. Thus, the difference between the genomic actions exerted by estrogen and raloxifene in human ovarian cancer cell lines expressing ERa appear to be dependent on the recruitment of co-regulators.
Introduction
Ovarian carcinoma results in more deaths than any other gynecological malignancy. In the vast majority of cases, it presents as advanced disease that is widespread in the abdominal cavity. Therefore, the majority of patients with ovarian cancer require treatment with cytotoxic chemotherapy after surgical management.
The molecular mechanisms involved in ovarian carcinogenesis are still unclear, but there is growing evidence that estrogens promote tumor progression in epithelial ovarian cancer. Estrogen receptor (ER) is present in B60% of cases of ovarian cancer (Rao and Slotman, 1991) . Although it was previously reported that estrogen replacement therapy (ERT) does not have a pronounced effect on the survival of patients with invasive ovarian carcinoma (Weiss and Rossing, 2001) , an association between ERT and ovarian cancer risk was recently reported (Lacey et al., 2002) . However, the mechanism by which estrogen induces carcinogenesis of ovarian tissue remains unclear. Many phenotypic alterations occur during multi-step ovarian carcinogenesis, including enhanced interaction of the tumor cells with peptide growth factors, activation of protooncogenes, and loss of tumor-suppressor genes (Chow et al., 1996) . ER can regulate gene transcription either directly by binding to the promoters of target genes or indirectly through a mechanism involving the binding of ER to other transcription factors such as Sp1 and AP1. Genes regulated indirectly by the latter type of ER binding include c-Myc (Dubik and Shiu, 1992 ) and insulin-like growth factor-I (IGF-1) (Umayahara et al., 1994) , whose promoters do not contain a classical ERE. It was reported that the expression of c-Myc and IGF-1 was detected in human ovarian cancer (Berns et al., 1992; van Dam et al., 1994) . In addition, estrogen is known to induce the expression of c-Myc and IGF-1 in the uterus (Murphy, 1991) and in breast cancer cells (Shang and Brown, 2002; Mawson et al., 2005) . However, the mechanism by which estrogen induces the expression of c-Myc and IGF-1 in ovarian tissue remains unknown. In the Women's Health Initiative (WHI) large prospective randomized controlled study, although women on the conjugated equine estrogen (CEE)-medroxyprogesterone acetate (MPA) arm had an increase in the relative risk of cardiovascular events and breast cancer (Rossouw et al., 2002) , the more recent reports on women on the CEE-only treatment arm did not show increased cardiovascular disease (Anderson et al., 2004) . Thus, the cardioprotective effect of estrogen itself was not ruled out by the results of the WHI study. Recently, we reported that MPA attenuates the induction by estrogen of both eNOS activity and NO production in human umbilical vein endothelial cells (HUVECs) (Oishi et al., 2004) . Thus, it is possible that progestin has adverse effects on the cardiovascular system, and therefore there is a need for an ideal estrogen analog that does not require the addition of progestin to protect the uterine endometrium. Raloxifene is a nonsteroidal benzothiophene that has been classified as a selective estrogen receptor modulator (SERM) based on the fact that it exerts estrogenagonistic effects on bone (Delmas et al., 1997) and lipid metabolism (Walsh et al., 1998) and estrogen-antagonistic effects on uterine endometrium (Delmas et al., 1997) and breast tissue (Cummings et al., 1999) . Although it was reported that raloxifene had no effect on the incidence of ovarian cancer (Neven et al., 2002) , its mechanism has yet to be proven.
We therefore examined the molecular mechanisms of the effects of estrogen and raloxifene on the gene expression of c-Myc and IGF-1 in human ovarian cancer cell lines. We report here the novel observation that estrogen induces the gene expression of c-Myc and IGF-1 via ERa by recruiting co-activators, whereas raloxifene has no effect on the gene expression of c-Myc and IGF-1 because it instead recruits co-repressors.
Results

Expression of ERa
We firstly examined the expression of ERa in different types of human ovarian cancer cell lines by Reverse Transcript-PCR. The equal level of b-actin expression in each sample was confirmed (Figure 1b) . The MCF-7 human breast cancer cell line was shown to express ERa as a positive control ( Figure 1b) . As we reported previously (Mabuchi et al., 2004b) , we confirmed that Caov-3 and OVCAR-3 cells expressed ERa, while A2780 cells did not (Figure 1a) . A clonal line of A2780 expressing functional ERa (A2780-ER) was made (Mabuchi et al., 2004b) and its expression of ERa was confirmed (Figure 1a) .
Expression of c-Myc and IGF-1
It is well known that estrogen reacts through the AP1 site of the promoter region of the target genes. Since the AP1 site exists in the promoter regions of the c-Myc and IGF-1 genes, the transcriptional responses of c-Myc and IGF-1 to estrogen and raloxifene were examined in human ovarian cancer cell lines. Estradiol (E2) induced the expression of both c-Myc and IGF-1 in Caov-3 (Figure 2a ), OVCAR-3 ( Figure 2b ) and A2780-ER (Figure 2d ) cells, but not in A2780 cells (Figure 2c ). On the other hand, raloxifene had no effect on the expression of c-Myc or IGF-1 in any of the cell lines. (Figure 3 ). In cells stimulated by E2 the transcription of c-Myc, an E2-responsive gene, was enhanced, indicating that E2 caused upregulation of c-Myc through transcriptional control. On the other hand, raloxifene did not have an apparent effect in the transcription of c-Myc.
ERa recruitment to ER target gene promoters
We then examined whether E2 and raloxifene enhance the binding of ERa to target gene promoters. Caov-3 cells were treated with E2 and raloxifene, and lysates of the cells were chromatin immunoprecipitated with antibody against ERa. The chromatin immunoprecipitation (ChIP)-captured DNA was subjected to PCR amplification using PCR primers located downstream and upstream of the AP1 site of the promoters of c-Myc and IGF-1. Both E2 and raloxifene induced the binding of ERa to the AP1 site of the promoter of c-Myc (Figure 4a ) and IGF-1 (Figure 4b ) in Caov-3, OVCAR-3 and A2780-ER cells, but not in A2780 cells.
Next, we examined whether E2 induced the expression of c-Myc via ERa using siRNA of ERa. We confirmed that the expression of ERa in Caov-3 cells transfected with siRNA of ERa was significantly lower than that in Caov-3 cells transfected with scramble siRNA (Figure 5a ). Whereas transfection with scramble siRNA had no effect on the E2-induced c-Myc expression (Figure 5b ), transfection with siRNA of ERa significantly inhibited the E2-induced c-Myc expression ( Figure 5c ). In addition, we examined the effect of ICI-182780 on the E2-induced increase of expression of c-Myc. Pretreatment with ICI-182780 significantly attenuated the E2-induced increase of expression of c-Myc ( Figure 6 ). 
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Figure 4 Estrogen receptor a (ERa) recruitment to ER target gene promoters. Caov-3, OVCAR-3, A2780 and A2780-ER cells were treated with 100 nM estradiol (E2) for 24 h or 1 mM raloxifene for 2 h and lysates were chromatin immunoprecipitated with antibody against ERa. The chromatin immunoprecipitation (ChIP)-captured DNA was subjected to PCR amplification using PCR primers located downstream and upstream of the AP1 site of the promoters of c-Myc (a) and insulin-like growth factor-I (IGF-1) (b). A representative example of an experiment that was repeated three times is shown. Difference between genomic actions of estrogen versus raloxifene H Sasaki et al Co-regulator recruitment to ER target gene promoters by E2 and raloxifene We next examined whether ERa-mediated transcriptional activation is associated with the recruitment of co-activators in human ovarian cancer cell lines. Cells were treated with E2 or raloxifene and lysates were chromatin immunoprecipitated with antibody against SRC-1 (Figure 7 , left panel), SRC-3 (Figure 7 , middle panel) or CBP (Figure 7, right panel) . The ChIPcaptured DNA was subjected to PCR amplification using PCR primers located downstream and upstream of the AP1 sites of the promoters of c-Myc (Figure 7a ) and IGF-1 (Figure 7b ). E2 induced the recruitment of SRC-1, -3 and CBP to the promoters of c-Myc and IGF-1 in Caov-3, OVCAR-3 and A2780-ER cells, but not in A2780 cells. On the other hand, raloxifene had no effect on the recruitment of SRC-1, -3 and CBP in any of these cell lines. We also tested two regions of the promoters, which did not contain the AP-1 site. Neither E2 nor raloxifene induced the binding of ERa to these regions of the promoters of c-Myc and IGF-1 in Caov-3. We thus confirmed that ER and raloxifene specifically induced the binding of ERa to the AP-1 site.
To elucidate the mechanism whereby raloxifene had no effect on the recruitment of SRC-1 and CBP even though raloxifene associated with ERa, we examined whether raloxifene recruits co-repressors to the promoters of the target genes. For this, Caov-3 cells were treated with E2 or raloxifene and lysates were chromatin immunoprecipitated with antibody against histone deacetylase2 (HDAC2) (Figure 8a ), nuclear receptor co-repressor (N-CoR) (Figure 8b ) or silencing mediator of repressed transcription (SMRT) (Figure 8c ). The ChIP-captured DNA was subjected to PCR amplification using PCR primers located downstream and upstream of the AP1 site of the promoter of IGF-1. Whereas E2 had no effect on the recruitment of HDAC2, N-CoR or SMRT to the promoter of IGF-1 (Figure 8 ), raloxifene induced the recruitment of HDAC2, N-CoR and SMRT to the promoter of IGF-1 (Figure 8 ).
Effect of SRC-1 silencing on E2-stimulated gene expression To determine whether SRC-1 expression was required for the E2-stimulated gene expression, we examined the effects of SRC-1 silencing on E2-stimulated c-Myc expression. We confirmed that the expression of SRC-1 in Caov-3 cells transfected with siRNA of SRC-1 was significantly lower than that in Caov-3 cells transfected with scramble siRNA (Figure 9a ). Whereas transfection with scramble siRNA had no effect on the E2-induced c-Myc expression, transfection with siRNA of SRC-1 significantly inhibited the E2-induced c-Myc expression (Figure 9b ). These results indicate that SRC-1 is a necessary determinant for the E2-induced c-Myc expression in human ovarian cancer cell lines.
Moreover, to determine whether SRC-1 expression was required for the growth-stimulatory effects of estrogen in human ovarian cancer cells, we examined the effects of SRC-1 silencing on E2-stimulated cellcycle progression in Caov-3 cells ( Figure 10) . As was the case for c-Myc expression (Figure 9b ), SRC-1 silencing abolished E2-stimulated cell-cycle progression. These results indicate that SRC-1 is a necessary determinant for the E2-stimulated cell-cycle progression in human ovarian cancer cells.
Discussion
One of the two novel findings in this study was that the induction of the expression of both c-Myc and IGF-1 by estrogen is due to its binding to ERa and subsequent recruitment of co-activators in human ovarian cancer cell lines expressing ERa. Another novel finding we made was that raloxifene had no effect on the expression of either c-Myc or IGF-1, due to its binding to ERa and subsequent recruitment of co-repressors in human ovarian cancer cell lines expressing ERa. These different genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines are novel findings.
ER is present in B60% of cases of ovarian cancer (Rao and Slotman, 1991) . Since E2 induces the expression of both c-Myc and IGF-1 in human ovarian cancer cell lines expressing ERa, but not in those not expressing ERa, ERT might induce ovarian cancer, as previously reported (Lacey et al., 2002) . When bound by raloxifene, ERa recruits co-repressors such as HDAC2, N-CoR and SMRT (Figure 8 ), and consequently exerts no effect on the expression of either c-Myc or IGF-1 (Figure 2 ) in human ovarian cancer cell lines expressing ERa, as raloxifene does in human breast and endometrial cancer cell lines (Shang and Brown, 2002) . The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a randomized study designed to determine whether raloxifene would reduce the risk of fracture in postmenopausal women with osteoporosis (Cauley ). The development of breast cancer was a secondary endpoint of the trial. At a median 48-month follow-up, raloxifene treatment resulted in a 72% reduction in breast cancer incidence without association with an increased risk of uterine endometrial cancer. Although there have been no reports of the effect of raloxifene on ovarian cancer, there is a possibility that raloxifene would be useful either for the inhibition of ERT-induced ovarian cancer or for human ovarian cancer chemoprevention, as suggested by the chemopreventive effect of raloxifene for breast cancer in a large clinical trial study of tamoxifen and raloxifene (STAR).
To examine the effect of E2 or raloxifene on ovarian cancer development, their effects on normal ovarian epithelial cells rather than ovarian cancer cell lines are now underway. It was reported that N-CoR expression is predictive of the response to tamoxifen in patients with ERa-positive breast tumors (Girault et al., 2003) . Does the expression of co-activators or co-repressors participate in the carcinogenesis of human ovarian cancer? It was reported that no significant difference in the expression of SRC-1, -2, -3 or N-CoR was found between epithelial ovarian tumors and the normal ovary (Hussein-Fikret and Fuller, 2005) . There were no detectable differences in the expression of SRC-1, -2, -3 or N-CoR among the human ovarian cancer cells in this study (data not shown). Thus, recruitment of co-activators or co-repressors rather than the expression of co-activators or co-repressors themselves may participate in the carcinogenesis of the human ovarian cancer. Further experiments will be required to test this.
Estrogen-mediated gene transcription in a specific tissue depends on several factors, the most important of which is the presence of at least one of the two nuclear ER isoforms, ERa and ERb. The presence and levels of Difference between genomic actions of estrogen versus raloxifene H Sasaki et al specific ER isoform variants, along with receptor co-activator, co-repressor and integrator proteins, directly modulate overall nuclear ER activity. It is known that the expression of ERa and ERb is differentially regulated during ovarian carcinogenesis (Cunat et al., 2004) . ERb is an important regulator of the proliferation and motility of ovarian cancer cells, and there is also evidence for a proapoptotic role of ERb, suggesting that the loss of ERb expression may be an important event leading to the development of ovarian cancer (Bardin et al., 2004) . Moreover, it was reported that ERb binds N-CoR and SMRT in the presence of agonists, but not antagonists, and that this binding also mediates co-activator recognition (Webb et al., 2003) . Thus, the ligand preference of ERb differs from that of ERa with respect to interactions with co-repressors, whose binding is inhibited by E2, and resembles that of ERb interactions with co-activators. Although transfection with siRNA of ERa significantly inhibited the E2-induced c-Myc expression (Figure 5c ), there is a still possibility that ERb plays an important role in mediating the different genomic actions between estrogen and raloxifene in human ovarian cancer cell lines.
In this study, both E2 and raloxifene exerted biological functions via nuclear transcription factor ERa, via a so-called 'genomic' mechanism. It was reported that when bound by E2 and raloxifene, ERa recruits co-activators and co-repressors, respectively, in breast cancer and uterine endometrial cancer cells (Shang and Brown, 2002) , and we showed here that similarly, when bound by E2 and raloxifene, ERa recruits co-activators and co-repressors, respectively, in human ovarian cancer cell lines. We previously reported that both E2 and raloxifene also exert biological effects via ERa, which are not related to its role as a nuclear transcription factor, via a so-called 'non-genomic' mechanism. For example, both E2 and raloxifene induce eNOS activity via a 'non-genomic' mechanism in vascular endothelial cells (Hisamoto et al., 2001a, b) . In addition, E2 induces the upregulation of telomerase activity via 'genomic' and 'non-genomic' mechanisms in breast cancer cells (Hisamoto et al., 2001a, b) and human ovarian cancer cells (Kimura et al., 2004) . Raloxifene blocks the E2-induced upregulation of telomerase activity via 'genomic' and 'non-genomic' mechanisms in breast cancer cells (Hisamoto et al., 2001a, b; Kawagoe et al., 2003) . Thus, the biological functions of raloxifene are different depending on the tissues, and crosstalk between the 'genomic' and 'nongenomic' mechanisms might be involved in the mechanisms of the actions of E2 and raloxifene. Therefore, there is still a possibility that a 'non-genomic' mechanism is involved in the regulation of the expression of c-Myc and IGF-1 by E2 and raloxifene in human ovarian cancer cell lines.
There was recently a report clarifying the properties of GPR30, a G protein-coupled receptor (GPCR) with characteristics that make it a candidate for the membrane estrogen-binding activity previously observed (Hewitt et al., 2005) . In addition, estrogen is known to induce Akt activation by GPR30 (36). Since we previously demonstrated that estrogen induces Akt activation in human ovarian cancer cells (Kimura et al., 2004; Revankar et al., 2005) and Caov-3 cells express Difference between genomic actions of estrogen versus raloxifene H Sasaki et al GPR30 (data not shown), experiments to examine whether GPR30 is involved in a 'non-genomic' mechanism in the regulation of the expression of c-Myc and IGF-1 by E2 and raloxifene are also now underway.
Materials and methods
Materials
Raloxifene, E2 and ICI-182780 were obtained from Sigma Chemical Co. (St Louis, MO, USA). The human ERa expression vector (pSG5-HEGO) was a kind gift from Dr P Chambon (Green et al., 1986 
Cell cultures
Human ovarian papillary adenocarcinoma cell line Caov-3 was obtained from American Type Culture Collection (Rockville, MD). The human ovarian cancer A2780 cell line derived from a patient prior to treatment was kindly provided by Dr T Tsuruo (Institute of Molecular and Cellular Biosciences, Tokyo, Japan) and Drs RF Ozols and TC Hamilton (Hamilton et al., 1985) . OVCAR-3 was purchased from the American Type Culture Collection (ATCC). The cells were cultured at 37 1C in Dulbecco's modified Eagles's medium with 10% fetal bovine serum in a water-saturated atmosphere of 95% air and 5% CO 2 .
Clone selection A2780 cells were transfected for 24 h in 6-well tissue culture plates with 4 mg of pSG5-HEGO and the neomycin resistance gene using Lipofectamine 2000 plus (Mabuchi et al., 2004a) . Clonal selection was performed by adding geneticin to the medium at 200 mg ml À1 final concentration 2 days after the transfection. After 3 weeks, several clones were isolated using cloning rings. Selected clones were then maintained in medium supplemented with geneticin (100 mg ml À1 ), and only low-passage cells (Po10) were used for the experiments, as described previously (22).
RT-PCR analysis of RNA Total RNA was extracted from cells with Tri Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) according to the manufacturer's instructions. cDNA was prepared from 1 mg of total RNA, primed with random hexamers (Invitrogen, Carlsbad, CA, USA), and reversetranscribed with Superscript II (Invitrogen) according to the manufacturer's protocol (Kimura et al., 2004) . Primers with the following sequences were prepared by Invitrogen c-Myc forward primer: 5 0 -GCCACGTCTCCACACATCAG-3 0 ; c-Myc reverse primer: 5 0 -TCTTGGCAGCAGGATAGTCCTT-3 0 ; and IGF-1 forward primer: 5 0 TGCTTCCGGAGCTG TGATC-3 0 ; IGF-I reverse primer: AGCTGACTTGGCA GGCTTGA. Typically, 1 ml aliquots of the reverse-transcribed cDNA were amplified by 25-35 cycles of PCR. Each cycle consisted of denaturation at 94 1C for 30 s, annealing at 55-60 1C for 30 s, and extension at 72 1C for 30-45 s. PCR products were separated by electrophoresis in a 2% agarose gel.
Real-time PCR
Caov-3 and A2780 cells were grown in phenol red-free DMEM supplemented with 10% charcoal-dextran-stripped FBS for at least 24 h and were treated with 100 nM E2 or 1 mM raloxifene for 2 h. The expression of c-Myc and IGF-1 mRNA was measured by real-time RT-PCR using an ABI PRISM 7000 Sequence Detector according to the manufacturer's protocol (Keeton and Brown, 2005) .
Nuclear run-on Nuclei were harvested for the nuclear run-on assay as described (Krystal et al., 1988) with the modification that, to minimize loss of weakly attached cells, monolayers were scraped into PBS without washing. Labeled RNA was purified after incubation of the nuclei with [
32 P]UTP. The targeted sequences (c-Myc) were cloned by PCR.
Targets were dotted onto nitrocellulose using a Bio-Rad filter manifold and baked at 80 1C for 2 h under vacuum. Prehybridization and hybridization were carried out as described (Celano et al., 1989) .
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out according to the manufacturer's protocol. Briefly, ovarian cancer cells were crosslinked with 1% HCHO for 10 min. Cell extracts were sonicated to sheer chromatin to an average size of B600 kb. The extract was divided into aliquots, and antibodies were added to the aliquots at a 1:100 dilution for immunoprecipitation. Antirabbit IgG antibody was used as a negative control. After immunoprecipitation, an aliquot of each captured immunocomplex was subjected to western analysis to confirm that the captured chromatin contained the transcriptional co-regulator corresponding to the specificity of the antibody that had been used for ChIP. For the remainder of the sample, crosslinks in the immunoprecipitated chromatin were reversed by heating with proteinase K at 65 1C overnight, and DNA was purified using a MinElute Reaction Cleanup kit (QIAGEN) and resuspended in 10 ml of 1 Â TE. The purified ChIP-captured DNA was analysed by PCR. The primers for ChIP were: c-Myc (À95 to À45) forward primer: 5 0 -AGGCGCGCGTAGT TAATTCAT; and c-Myc reverse primer: CGCCCTCT GCTTTGGGA-3 0 . IGF-I (À111 to À312) forward primer: 5 0 -TTGTCACCATGCCCAAAAAA-3 0 ; and IGF-I reverse primer: 5 0 -TTGCGCAGGCTCTATCTGC-3 0 .
SiRNA transfection
One day before transfection, cells were plated in 2 ml of growth medium without antibiotics such that they would be 30-50% confluent at the time of transfection. For the transfection of each sample, oligomer-Lipofectamine 2000 complexes were prepared as follows: 100 pmol of siRNA oligomer was diluted in 250 ml of DMEM Reduced Serum Medium without serum. Lipofectamine 2000 was mixed gently before use, and then 5 ml of it was diluted in 250 ml of DMEM I Reduced Serum Medium, mixed gently and incubated for 5 min at room temperature. After the 5-min incubation, the diluted oligomer was combined with the diluted Lipofectamine 2000, mixed gently and incubated for 20 min at room temperature. The oligomer-Lipofectamine 2000 complexes were added to each well containing cells and medium, and mixed gently by rocking the plate back and forth. The cells were incubated at 37 1C in a CO 2 incubator for 48 h and then subjected to the assay for gene knockdown. The medium was changed after 24 h (Hayakawa et al., 2004) .
Cell cycle entry assay
For cell cycle entry analysis, transfected Caov-3 cells were treated with ethanol, 100 nM E2 or 1 mM raloxifene for 24 h before trypsinization, washing in PBS and fixation in 70% ethanol. Fixed cells were treated with ribonuclease A (0.5 mg ml
À1
) for 30 min at 37 1C. The cells were then stained with an equal volume of propidium iodide (69 M in 38 mM sodium citrate, pH 7.4) for at least 1 h and analysed for DNA content by flow cytometry (FACS sorting) at a core facility (Keeton and Brown, 2005) .
Statistics
Statistical analysis was performed using one-way ANOVA followed by Fisher's least significant difference test, and Po0.05 was considered significant. Data are expressed as the mean ± s.e.
